Waverton Investment Management Ltd lessened its holdings in Pfizer Inc. (NYSE:PFE) by 5.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 156,209 shares of the biopharmaceutical company’s stock after selling 8,292 shares during the quarter. Pfizer accounts for 0.3% of Waverton Investment Management Ltd’s investment portfolio, making the stock its 29th largest position. Waverton Investment Management Ltd’s holdings in Pfizer were worth $5,667,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Fort L.P. bought a new position in Pfizer in the 2nd quarter worth about $121,000. Braun Bostich & Associates Inc. bought a new position in Pfizer in the 1st quarter worth about $139,000. Smart Portfolios LLC boosted its stake in Pfizer by 43.9% in the 2nd quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 1,200 shares during the period. Goodwin Daniel L bought a new position in Pfizer in the 2nd quarter worth about $171,000. Finally, Point72 Hong Kong Ltd boosted its stake in Pfizer by 7,195.5% in the 2nd quarter. Point72 Hong Kong Ltd now owns 4,815 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 4,749 shares during the period. Hedge funds and other institutional investors own 69.42% of the company’s stock.
Several analysts have weighed in on the company. Morgan Stanley set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, August 29th. Morningstar set a $46.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, August 28th. BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 price target on shares of Pfizer in a report on Monday, August 27th. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, August 27th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $42.00 price target on shares of Pfizer in a report on Thursday, August 23rd. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average target price of $43.27.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. Pfizer’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period last year, the firm posted $0.67 EPS. As a group, equities analysts expect that Pfizer Inc. will post 3 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.10%. Pfizer’s dividend payout ratio is 51.32%.
In other news, major shareholder Pfizer Inc acquired 55,556 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the acquisition, the insider now owns 21,976,484 shares in the company, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Holdings Cut by Waverton Investment Management Ltd” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2018/12/08/pfizer-inc-pfe-holdings-cut-by-waverton-investment-management-ltd.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: What are Closed-End Mutual Funds?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.